These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35081479)

  • 1. Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.
    Shi S; Du Y; Huang L; Cui J; Niu J; Xu Y; Zhu Q
    Bioorg Chem; 2022 Mar; 120():105605. PubMed ID: 35081479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686.
    Li Q; Guo Q; Wang S; Wan S; Li Z; Zhang J; Wu X
    Eur J Med Chem; 2022 Aug; 238():114455. PubMed ID: 35594654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins.
    Du Y; Shi S; Shu C; He Y; Xu W; Wu D; Tian Y; Kong M; He J; Xie W; Qiu Y; Xu Y; Zou Y; Zhu Q
    Eur J Med Chem; 2024 Jun; 272():116489. PubMed ID: 38759458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.
    Zhao HY; Wang HP; Mao YZ; Zhang H; Xin M; Xi XX; Lei H; Mao S; Li DH; Zhang SQ
    J Med Chem; 2022 Mar; 65(6):4709-4726. PubMed ID: 35254067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of highly potent and selective CRBN-recruiting EGFR
    Zhang W; Li P; Sun S; Jia C; Yang N; Zhuang X; Zheng Z; Li S
    Eur J Med Chem; 2022 Aug; 238():114509. PubMed ID: 35691176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC).
    Zhang H; Zhao HY; Xi XX; Liu YJ; Xin M; Mao S; Zhang JJ; Lu AX; Zhang SQ
    Eur J Med Chem; 2020 Mar; 189():112061. PubMed ID: 31951960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of potent small molecule PROTACs targeting mutant EGFR.
    Zhao HY; Yang XY; Lei H; Xi XX; Lu SM; Zhang JJ; Xin M; Zhang SQ
    Eur J Med Chem; 2020 Dec; 208():112781. PubMed ID: 32883633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting EGFR degradation by autophagosome degraders.
    Zhu Z; Li J; Shen S; Al-Furas H; Li S; Tong Y; Li Y; Zeng Y; Feng Q; Chen K; Ma N; Zhou F; Zhang Z; Li Z; Pang J; Ding K; Xu F
    Eur J Med Chem; 2024 Apr; 270():116345. PubMed ID: 38564826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide.
    He K; Zhang Z; Wang W; Zheng X; Wang X; Zhang X
    Bioorg Med Chem Lett; 2020 Jun; 30(12):127167. PubMed ID: 32317208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Epidermal Growth Factor Receptor in Non-Small-Cell-Lung Cancer: Current State and Future Perspective.
    Bao SM; Hu QH; Yang WT; Wang Y; Tong YP; Bao WD
    Anticancer Agents Med Chem; 2019; 19(8):984-991. PubMed ID: 30868964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders.
    Li P; Li B; Yang N; Xu T; Zheng Z
    Expert Opin Ther Pat; 2023; 33(7-8):477-492. PubMed ID: 37873645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
    Cheng M; Yu X; Lu K; Xie L; Wang L; Meng F; Han X; Chen X; Liu J; Xiong Y; Jin J
    J Med Chem; 2020 Feb; 63(3):1216-1232. PubMed ID: 31895569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of selective degraders of EGFR
    Zhang X; Xu F; Tong L; Zhang T; Xie H; Lu X; Ren X; Ding K
    Eur J Med Chem; 2020 Apr; 192():112199. PubMed ID: 32171162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the development of EGFR degraders: PROTACs and LYTACs.
    Hong D; Zhou B; Zhang B; Ren H; Zhu L; Zheng G; Ge M; Ge J
    Eur J Med Chem; 2022 Sep; 239():114533. PubMed ID: 35728507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
    Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
    Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations.
    Dong Q; Yu P; Ye L; Zhang J; Wang H; Zou F; Tian J; Kurihara H
    Sci Rep; 2019 Apr; 9(1):5692. PubMed ID: 30952931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of highly potent and selective EGFR
    Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
    Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
    Lavacchi D; Mazzoni F; Giaccone G
    Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
    Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
    PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.